Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by L JEFFREY MEDEIROS and SANAM LOGHAVI.
L JEFFREY MEDEIROS
Connection Strength
6.570
SANAM LOGHAVI
  1. A rare histologic variant of a common lymphoma. Blood. 2016 12 22; 128(25):3012.
    View in: PubMed
    Score: 0.575
  2. Epstein-Barr virus-positive plasmacytoma in immunocompetent patients. Histopathology. 2015 Aug; 67(2):225-34.
    View in: PubMed
    Score: 0.506
  3. Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia. Am J Hematol. 2024 Oct; 99(10):1959-1968.
    View in: PubMed
    Score: 0.243
  4. Myeloid neoplasm with <10% blasts and t(3;5)(q25.1;q34)/NPM::MLF1: A classification dilemma. Am J Hematol. 2024 Sep; 99(9):1827-1829.
    View in: PubMed
    Score: 0.237
  5. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol. 2022 11; 35(11):1677-1683.
    View in: PubMed
    Score: 0.210
  6. Laboratory Evaluation and Pathological Workup of Neoplastic Monocytosis - Chronic Myelomonocytic Leukemia and Beyond. Curr Hematol Malig Rep. 2021 06; 16(3):286-303.
    View in: PubMed
    Score: 0.194
  7. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol. 2021 03; 192(6):1054-1063.
    View in: PubMed
    Score: 0.192
  8. Next-Generation Scholarship: Rebranding Hematopathology Using Twitter: The MD Anderson Experience. Mod Pathol. 2021 05; 34(5):854-861.
    View in: PubMed
    Score: 0.188
  9. Social Media for Hematopathologists: Medical Practice Reinvented-#Hemepath. Curr Hematol Malig Rep. 2020 10; 15(5):383-390.
    View in: PubMed
    Score: 0.188
  10. Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor. Leuk Lymphoma. 2020 12; 61(13):3243-3246.
    View in: PubMed
    Score: 0.184
  11. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Ann Diagn Pathol. 2019 Aug; 41:38-42.
    View in: PubMed
    Score: 0.170
  12. Ultra-Rapid Reporting of GENomic Targets (URGENTseq): Clinical Next-Generation Sequencing Results within 48?Hours of Sample Collection. J Mol Diagn. 2019 01; 21(1):89-98.
    View in: PubMed
    Score: 0.165
  13. Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption. Hum Pathol. 2018 12; 82:215-231.
    View in: PubMed
    Score: 0.161
  14. Breast Implant-Associated Anaplastic Large Cell Lymphoma With Bone Marrow Involvement. Aesthet Surg J. 2018 Jun 13; 38(7).
    View in: PubMed
    Score: 0.159
  15. Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. J Cutan Pathol. 2017 Dec; 44(12):1075-1079.
    View in: PubMed
    Score: 0.152
  16. Characteristics and clinical implications of reactive germinal centers in the bone marrow. Hum Pathol. 2017 10; 68:7-21.
    View in: PubMed
    Score: 0.147
  17. Herpes simplex infection simulating Richter transformation: a series of four cases and review of the literature. Histopathology. 2017 Apr; 70(5):821-831.
    View in: PubMed
    Score: 0.145
  18. Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology. Leuk Lymphoma. 2016 12; 57(12):2804-2812.
    View in: PubMed
    Score: 0.137
  19. TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis. Br J Haematol. 2015 Oct; 171(1):91-9.
    View in: PubMed
    Score: 0.130
  20. Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood. 2015 May 21; 125(21):3360-3.
    View in: PubMed
    Score: 0.129
  21. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol. 2014 Oct 04; 7:74.
    View in: PubMed
    Score: 0.123
  22. The spectrum of hematologic neoplasms in patients with Li-Fraumeni syndrome. Am J Hematol. 2024 Dec; 99(12):2416-2419.
    View in: PubMed
    Score: 0.062
  23. Diagnostic utility of immunohistochemistry in detection of NPM1 mutations in acute myeloid leukemia with a patchy distribution. EJHaem. 2024 Apr; 5(2):379-382.
    View in: PubMed
    Score: 0.059
  24. Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms. Mod Pathol. 2024 Feb; 37(2):100397.
    View in: PubMed
    Score: 0.058
  25. Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection. Cytometry B Clin Cytom. 2023 Sep; 104(5):356-366.
    View in: PubMed
    Score: 0.057
  26. DDX41 mutations in patients with non-myeloid hematologic neoplasms. Am J Hematol. 2023 08; 98(8):E193-E196.
    View in: PubMed
    Score: 0.056
  27. Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma?variant. Virchows Arch. 2023 Jun; 482(6):1011-1019.
    View in: PubMed
    Score: 0.055
  28. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology. 2023 Jun; 55(4):514-524.
    View in: PubMed
    Score: 0.055
  29. Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms. Biology (Basel). 2022 Dec 21; 12(1).
    View in: PubMed
    Score: 0.054
  30. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood. 2022 07 07; 140(1):58-72.
    View in: PubMed
    Score: 0.053
  31. Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy. Leuk Res. 2022 07; 118:106860.
    View in: PubMed
    Score: 0.052
  32. Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. Leuk Res. 2022 05; 116:106827.
    View in: PubMed
    Score: 0.052
  33. Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. Leukemia. 2022 05; 36(5):1343-1350.
    View in: PubMed
    Score: 0.052
  34. Non-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis. Am J Hematol. 2022 03 01; 97(3):E100-E102.
    View in: PubMed
    Score: 0.051
  35. Value and pitfalls of assessing bone marrow morphologic findings to predict response in patients with myelofibrosis who undergo hematopoietic stem cell transplantation. Ann Diagn Pathol. 2022 Feb; 56:151860.
    View in: PubMed
    Score: 0.050
  36. Future of Education or Present Reality? Arch Pathol Lab Med. 2021 11 01; 145(11):1350-1354.
    View in: PubMed
    Score: 0.050
  37. Hematogones with light chain restriction: A potential diagnostic pitfall when using flow cytometry analysis to assess bone marrow specimens. Leuk Res. 2021 12; 111:106704.
    View in: PubMed
    Score: 0.050
  38. Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenomenon. Leuk Lymphoma. 2021 12; 62(13):3296-3299.
    View in: PubMed
    Score: 0.049
  39. Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. Haematologica. 2021 04 01; 106(4):1047-1055.
    View in: PubMed
    Score: 0.048
  40. Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases. Mod Pathol. 2021 06; 34(6):1143-1152.
    View in: PubMed
    Score: 0.048
  41. Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities. Mod Pathol. 2021 02; 34(2):300-313.
    View in: PubMed
    Score: 0.047
  42. Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features. Blood Cancer J. 2020 08 26; 10(8):86.
    View in: PubMed
    Score: 0.046
  43. Immunopathology of Kikuchi-Fujimoto disease: A reappraisal using novel immunohistochemistry markers. Histopathology. 2020 Aug; 77(2):262-274.
    View in: PubMed
    Score: 0.046
  44. Systematic use of fluorescence in-situ hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasms. Histopathology. 2020 06; 76(7):1042-1054.
    View in: PubMed
    Score: 0.045
  45. t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm? Ann Hematol. 2020 Mar; 99(3):487-500.
    View in: PubMed
    Score: 0.045
  46. RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD. Cancer Med. 2020 02; 9(3):849-858.
    View in: PubMed
    Score: 0.044
  47. A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma. Mod Pathol. 2020 03; 33(3):367-379.
    View in: PubMed
    Score: 0.043
  48. Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Br J Haematol. 2019 08; 186(4):538-548.
    View in: PubMed
    Score: 0.042
  49. PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers (Basel). 2019 May 19; 11(5).
    View in: PubMed
    Score: 0.042
  50. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol. 2019 07; 94(7):757-766.
    View in: PubMed
    Score: 0.042
  51. P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival. Am J Hematol. 2018 11; 93(11):1376-1383.
    View in: PubMed
    Score: 0.041
  52. Characterization of chronic myelomonocytic leukemia with TP53 mutations. Leuk Res. 2018 07; 70:97-99.
    View in: PubMed
    Score: 0.040
  53. MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma. 2019 01; 60(1):37-48.
    View in: PubMed
    Score: 0.040
  54. Chronic lymphoproliferative disorder of NK-cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools. Eur J Haematol. 2018 May; 100(5):444-454.
    View in: PubMed
    Score: 0.039
  55. Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing. Oncotarget. 2018 Feb 02; 9(9):8441-8449.
    View in: PubMed
    Score: 0.039
  56. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis. Leuk Res. 2018 02; 65:25-28.
    View in: PubMed
    Score: 0.039
  57. Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors. Oncotarget. 2018 02 13; 9(12):10259-10271.
    View in: PubMed
    Score: 0.038
  58. Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia. Blood Cancer J. 2017 07 14; 7(7):e583.
    View in: PubMed
    Score: 0.037
  59. Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm. Am J Hematol. 2017 Jun; 92(6):520-528.
    View in: PubMed
    Score: 0.037
  60. Immunophenotypic Shifts in Primary Cutaneous ?d T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens. Am J Surg Pathol. 2017 Apr; 41(4):431-445.
    View in: PubMed
    Score: 0.037
  61. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. Eur J Haematol. 2017 Apr; 98(4):415-421.
    View in: PubMed
    Score: 0.036
  62. Histologic transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol. 2016 10; 91(10):1036-43.
    View in: PubMed
    Score: 0.035
  63. Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2016 07; 16(7):395-403.e1.
    View in: PubMed
    Score: 0.034
  64. High-grade Transformation of Low-grade B-cell Lymphoma: Pathology and Molecular Pathogenesis. Am J Surg Pathol. 2016 Jan; 40(1):e1-16.
    View in: PubMed
    Score: 0.034
  65. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leuk Lymphoma. 2016 May; 57(5):1104-13.
    View in: PubMed
    Score: 0.034
  66. Clinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms. Am J Clin Pathol. 2015 Nov; 144(5):746-55.
    View in: PubMed
    Score: 0.033
  67. Clinicopathologic, Immunophenotypic, Cytogenetic, and Molecular Features of ?d T-Cell Large Granular Lymphocytic Leukemia: An Analysis of 14 Patients Suggests Biologic Differences With a? T-Cell Large Granular Lymphocytic Leukemia. [corrected]. Am J Clin Pathol. 2015 Oct; 144(4):607-19.
    View in: PubMed
    Score: 0.033
  68. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2015 Nov; 171(4):509-16.
    View in: PubMed
    Score: 0.033
  69. Waldenstr?m macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol. 2015 Jun 24; 8:74.
    View in: PubMed
    Score: 0.032
  70. Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin. Hum Pathol. 2015 Apr; 46(4):558-69.
    View in: PubMed
    Score: 0.031
  71. Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Mod Pathol. 2015 Mar; 28(3):373-82.
    View in: PubMed
    Score: 0.031
  72. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. Leukemia. 2016 Feb; 30(2):361-72.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.